Intravitreal (IVT) Injectables Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Intravitreal (IVT) Injectables Market Trends and Insights

Rising Prevalence of Retinal Diseases and Diabetes

The Intravitreal (IVT) injectables market is supported by a growing number of people living with diabetes and by the wider identification of retinal complications in routine diabetes care. Diabetic retinopathy affects 1 in 3 people with diabetes. The International Diabetes Federation projected the adult diabetes population to rise from 537 million in 2021 to 783 million by 2045. Growth is concentrated in low- and middle-income countries in South and Southeast Asia, where eye-care capacity is also improving. A U.S. retrospective analysis of 571,545 intravitreal injections across 238 million patient records found that diabetic eye disease represented 26.9% of treated diagnoses, and annual injection volume tripled between 2017 and 2023. Screening programs and wider use of treatment in proliferative disease bring more patients into active care.

Aging Population and Increasing Age-Related Macular Degeneration

The market also benefits from the increasing number of older patients with age-related macular degeneration, or AMD. A Global Burden of Disease analysis reported 8.06 million people with AMD-related vision impairment in 2021 and projected 21.34 million by 2050. The increase reflects demographic change more than any reduction in disease burden from current treatment patterns. The same analysis found that removing tobacco exposure could reduce projected 2050 AMD cases by 9%. Japan provides an early view of demand in aging Asian populations because it has high prevalence among people older than 70 and a developed reimbursement system. These conditions support recurring treatment demand in established retinal-care systems.

Longer-Acting Delivery Platforms Reducing Injection Burden

Longer-acting products are changing treatment patterns in the Intravitreal (IVT) injectables market by reducing the frequency of eligible follow-up injections. Regeneron received FDA approval in April 2026 for EYLEA HD dosing intervals of up to 20 weeks in wet AMD and diabetic macular edema after 1 year of demonstrated response^{[1]Regeneron Pharmaceuticals, Inc., “EYLEA HD Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months,” Regeneron}. Roche received a CE mark for Contivue, its Susvimo Port Delivery Platform, in September 2025. Roche also received a positive CHMP opinion for Susvimo in July 2026 and FDA approval for diabetic retinopathy in May 2025. These options may shift more treatment activity toward specialist sites that can manage advanced administration pathways. Roche also reported sustained 2-year results for Vabysmo in polypoidal choroidal vasculopathy in August 2026.

Growth of Biosimilar and Lower-Cost Retinal Therapies

Biosimilars are reshaping the cost and access profile of the Intravitreal (IVT) injectables market, particularly in established anti-VEGF treatment pathways. Biocon received FDA approval for Yesafili in May 2024, while Celltrion received FDA approval for EYDENZELT in October 2025^{[2]Biocon Biologics Ltd., “Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili,” Biocon Biologics}. Sandoz and Samsung Bioepis obtained European Commission approvals for Afqlir and Opuviz in November 2024. Lower-cost alternatives can increase affordability for treatment-eligible patients who do not receive therapy today. They also intensify pressure on originator products and hospital formularies. Regulatory decisions on substitution and formulary placement will determine which products gain broad use.

High Treatment Cost and Reimbursement Restrictions

Treatment costs limit access in the Intravitreal (IVT) injectables market, especially where coverage is incomplete or patients face substantial out-of-pocket obligations. U.S. wholesale acquisition costs in 2023 ranged from USD 50 to USD 80 per dose for off-label bevacizumab, USD 1,957.50 for aflibercept 2 mg, USD 2,190 for faricimab, and USD 2,625 for aflibercept 8 mg. The Medicare Part B deductible is USD 283 in 2026, and Original Medicare patients face 20% coinsurance. UnitedHealthcare used step-therapy requirements for VEGF inhibitors in its 2025 commercial medical benefit policy. A 2025 survey found that 85% of retina specialists were concerned about patient access during a compounded bevacizumab shortage, and 63.9% expected treatment-plan changes. Such limits can delay initiation and increase reliance on lower-cost treatments.

Treatment Fatigue, Missed Doses, and Patient Dropout

Treatment fatigue constrains the Intravitreal (IVT) injectables market because many therapies require repeated clinic visits over long treatment periods. A 2026 study of 657 patients on pro re nata anti-VEGF protocols found that 52.8% met lost-to-follow-up criteria. Among contacted patients, 56% cited a belief that they were cured, 26% cited fear of injections, 28% cited travel difficulties, and 15% cited time burden. A 2025 study also found that 28.5% of a real-world AMD cohort discontinued therapy, with poorer visual acuity predicting clinician-led discontinuation. Extended-interval regimens can reduce travel and injection anxiety for some patients. Their uptake could improve continuity of care when the clinical response remains durable.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Anti-VEGF Agents Lead While Corticosteroids Grow Faster

Anti-VEGF agents held 87.31% of the intravitreal (IVT) injectables market share in 2025. Their position reflects broad use in AMD, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Prescribers also have long experience with anti-VEGF injection protocols. Faricimab was the first bispecific antibody approved for the eye in the United States in January 2022. U.S. injection rates for faricimab increased more than 5-fold from 2022 to 2023, and the product surpassed ranibizumab use within its first 2 years. The pattern indicates that clinicians may change products when longer durability is established.

Corticosteroids are forecast to be the fastest-growing product type at a 7.65% CAGR through 2031. Their use is increasing in uveitis, refractory diabetic macular edema, and cases with an inadequate anti-VEGF response. Antibiotics and antivirals continue to serve smaller roles in endophthalmitis and viral retinitis. Their demand is linked to the number of intravitreal procedures rather than to the incidence of the main retinal diseases. Antifungals remain the smallest category because use is limited to immunocompromised populations. Biosimilar competition is likely to move investment toward extended-interval products and gene therapies across the Intravitreal (IVT) injectables industry.

By Indication: AMD Leads While Diabetic Retinopathy Expands

AMD held 32.24% of the revenue share in 2025. Its scale rests on clinical evidence, established payer support, and a growing older population in North America, Europe, and Japan. Many patients require ongoing anti-VEGF treatment to maintain vision. The age profile of these regions supports continued demand for retinal services across the Intravitreal (IVT) injectables market. Established care pathways also make AMD a durable source of procedure volume. AMD does not have the highest forecast growth rate among the indications.

Diabetic retinopathy is forecast to grow at an 8.22% CAGR from 2026 to 2031. Rising diabetes prevalence increases the pool of patients at risk of retinal damage. Wider use of anti-VEGF therapy in proliferative diabetic retinopathy can replace or defer panretinal photocoagulation in selected patients. Longer-interval options may also help patients who struggle with monthly or every-2-month schedules. EYLEA HD received FDA approval for macular edema following retinal vein occlusion in November 2025. Uveitis, endophthalmitis, and other retinal disorders remain smaller indications with steady treatment needs.

By End User: Hospitals Lead While Specialized Clinics Expand

Hospitals held 55.14% of the revenue share in 2025. Sterile preparation needs, specialist access, and emergency capability support their role. The American Academy of Ophthalmology identified endophthalmitis, retinal detachment, cataract development, and sustained elevated intraocular pressure as serious complications that require prompt specialist response^{[3]American Academy of Ophthalmology, “Intravitreal Injections, 2025 Clinical Statement,” American Academy of Ophthalmology}. These requirements have historically favored hospital care in the Intravitreal (IVT) injectables market. Hospital injection centers also face pressure to manage volume and costs efficiently. This creates room for other supervised treatment settings.

Specialty ophthalmology clinics are forecast to grow at an 8.42% CAGR through 2031. These clinics can concentrate retinal expertise and improve throughput per injection chair. They may also offer shorter scheduling windows than hospital outpatient departments. A 2026 survey found that 46% of practices increased in-office procedures to address limited hospital operating-room access. Ambulatory surgical centers have a role where facility reimbursement supports operations. Mobile injection units and nursing-led services remain small but can support task-sharing where specialist availability is limited.

By Distribution Channel: Hospital Pharmacies Lead While Online Pharmacies Accelerate

Hospital pharmacies held 36.54% of the revenue share in 2025. Most intravitreal procedures require dispensing at the care site in a controlled setting. Anti-VEGF agents and corticosteroids are often physician-administered biologics covered under medical benefits. This payment structure directs much of the volume through institutional channels in the Intravitreal (IVT) injectables market. Retail pharmacies retain a role in systems that support compounded bevacizumab, biosimilar programs, or prefilled-syringe supply. They can also serve smaller satellite clinics under appropriate handling arrangements.

Online pharmacies are forecast to grow at a 9.12% CAGR from 2026 to 2031. Their activity is centered on delivery to clinics, patient-assistance fulfillment, and distribution partnerships rather than unsupervised home injections. Pre-filled syringe delivery can support facilities using extended-interval therapy. Interchangeable biosimilar classifications in the United States may allow substitution at dispensing under applicable rules. Better cold-chain logistics and biologics packaging reduce distribution barriers. These changes can redirect some incremental supply activity within the Intravitreal (IVT) injectables market.

Geography Analysis

North America held 38.61% of the Intravitreal (IVT) injectables market share in 2025. The region has a high concentration of retina specialists, active clinical trials, and broad reimbursement for branded anti-VEGF therapies. Payer pressure still affects treatment choice and payment levels. Biocon confirmed the Canadian launch of Yesafili no later than July 2025. Mexico is attracting interest as private ophthalmology networks extend coverage in major cities.

Europe remains the second-largest geography in the Intravitreal (IVT) injectables market. Germany, the United Kingdom, France, Italy, and Spain have established reimbursement pathways for anti-VEGF treatment. European Commission approvals for Afqlir and Opuviz in November 2024 broadened biosimilar choice. Hospital tenders can alter product use quickly after a new biosimilar enters the formulary. The United Kingdom has used off-label bevacizumab to control costs, and approved lower-cost options may gain further use.

Asia-Pacific is forecast to expand at an 8.65% CAGR from 2026 to 2031 in the Intravitreal (IVT) injectables market. Aging populations, diabetes, and improving ophthalmology infrastructure are supporting regional demand. Santen launched the EYLEA 8 mg prefilled syringe in Japan on May 21, 2025, at JPY 146,286 (USD 970). Novartis received Japanese approval for Beovu in proliferative diabetic retinopathy in November 2025. India has substantial unmet need and an affordability gap, while regulatory pathways for ophthalmic biologics are developing. The Middle East and Africa and South America remain smaller but increasingly relevant as biosimilar pricing supports access.